Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07526116) titled 'A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults' on April 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Regeneron Pharmaceuticals
Condition:
Healthy Volunteer
Intervention:
Drug: REGN22044
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: May 7, 2026
Target Sample Size: 64
To know more, visit https://clinicaltrial...